Nombre del producto:1-Ethyl-4-(4-nitrophenyl)piperazine

IUPAC Name:1-ethyl-4-(4-nitrophenyl)piperazine

CAS:115619-00-6
Fórmula molecular:C12H17N3O2
Pureza:95%
Número de catálogo:CM120162
Peso molecular:235.29

Unidad de embalaje Stock disponible Precio($) Cantidad
CM120162-5g in stock ƥŗ
CM120162-10g in stock ƈľľ
CM120162-25g in stock Ǚƥŗ
CM120162-100g 1-2 Weeks ȃIJƥ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :115619-00-6
Fórmula molecular:C12H17N3O2
Punto de fusión:-
Código de sonrisas:O=[N+](C1=CC=C(N2CCN(CC)CC2)C=C1)[O-]
Densidad:
Número de catálogo:CM120162
Peso molecular:235.29
Punto de ebullición:
Nº Mdl:MFCD00614372
Almacenamiento:Store at room temperature.

Category Infos

Piperazines
Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.

Column Infos

Infigratinib
Sept. 06, 2023, positive feedback from the U.S. FDA and the EU EMA on key elements of the trial design for PROPEL3, its pivotal Phase 3 study of infigratinib in children with achondroplasia.
Achondroplasia is the most common cause of disproportionate short stature, affecting approximately 55,000 people in the United States and European Union, including up to 10,000 children and adolescents with open growth plates. Achondroplasia impacts overall health and quality of life, leading to medical complications such as obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis. The condition is uniformly caused by an activating mutation in FGFR3.
Infigratinib is an oral small molecule designed to inhibit FGFR3 and target achondroplasia at its source. It is incredibly exciting that infigratinib has the potential to become the first effective oral treatment option to improve growth, enhance functionality and decrease complications.

Related Products